JP2012517592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517592A5 JP2012517592A5 JP2011549275A JP2011549275A JP2012517592A5 JP 2012517592 A5 JP2012517592 A5 JP 2012517592A5 JP 2011549275 A JP2011549275 A JP 2011549275A JP 2011549275 A JP2011549275 A JP 2011549275A JP 2012517592 A5 JP2012517592 A5 JP 2012517592A5
- Authority
- JP
- Japan
- Prior art keywords
- measured concentration
- future
- subject
- renal
- threshold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003907 kidney function Effects 0.000 claims 35
- 201000011040 acute kidney failure Diseases 0.000 claims 26
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 21
- 208000033626 Renal failure acute Diseases 0.000 claims 21
- 208000012998 acute renal failure Diseases 0.000 claims 16
- 238000003556 assay Methods 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 230000006378 damage Effects 0.000 claims 11
- 208000020832 chronic kidney disease Diseases 0.000 claims 10
- 210000003734 kidney Anatomy 0.000 claims 9
- 230000007423 decrease Effects 0.000 claims 8
- 206010019280 Heart failures Diseases 0.000 claims 6
- 238000012959 renal replacement therapy Methods 0.000 claims 6
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 claims 5
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 claims 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims 5
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 5
- 108010063045 Lactoferrin Proteins 0.000 claims 5
- 102000012174 Lactotransferrin Human genes 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 208000028208 end stage renal disease Diseases 0.000 claims 5
- 201000000523 end stage renal failure Diseases 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 5
- 108010047303 von Willebrand Factor Proteins 0.000 claims 5
- 102100036537 von Willebrand factor Human genes 0.000 claims 5
- 229960001134 von willebrand factor Drugs 0.000 claims 5
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 claims 4
- 101710180007 Beta-2-glycoprotein 1 Proteins 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000010839 body fluid Substances 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims 3
- 206010061481 Renal injury Diseases 0.000 claims 3
- 231100000637 nephrotoxin Toxicity 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims 2
- 108010051457 Acid Phosphatase Proteins 0.000 claims 2
- 102000013563 Acid Phosphatase Human genes 0.000 claims 2
- 206010062237 Renal impairment Diseases 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 208000037806 kidney injury Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 231100000857 poor renal function Toxicity 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 238000013517 stratification Methods 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15039309P | 2009-02-06 | 2009-02-06 | |
| US15037209P | 2009-02-06 | 2009-02-06 | |
| US15037409P | 2009-02-06 | 2009-02-06 | |
| US61/150,393 | 2009-02-06 | ||
| US61/150,372 | 2009-02-06 | ||
| US61/150,374 | 2009-02-06 | ||
| US16240209P | 2009-03-23 | 2009-03-23 | |
| US16239609P | 2009-03-23 | 2009-03-23 | |
| US61/162,402 | 2009-03-23 | ||
| US61/162,396 | 2009-03-23 | ||
| US16633309P | 2009-04-03 | 2009-04-03 | |
| US61/166,333 | 2009-04-03 | ||
| PCT/US2010/023292 WO2010091231A1 (en) | 2009-02-06 | 2010-02-05 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013153A Division JP2015096870A (ja) | 2009-02-06 | 2015-01-27 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517592A JP2012517592A (ja) | 2012-08-02 |
| JP2012517592A5 true JP2012517592A5 (enExample) | 2013-03-28 |
Family
ID=42542388
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549275A Pending JP2012517592A (ja) | 2009-02-06 | 2010-02-05 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
| JP2015013153A Pending JP2015096870A (ja) | 2009-02-06 | 2015-01-27 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
| JP2016132688A Pending JP2016194526A (ja) | 2009-02-06 | 2016-07-04 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013153A Pending JP2015096870A (ja) | 2009-02-06 | 2015-01-27 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
| JP2016132688A Pending JP2016194526A (ja) | 2009-02-06 | 2016-07-04 | 腎損傷および腎不全の診断および予後診断のための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160123996A1 (enExample) |
| EP (1) | EP2393937A4 (enExample) |
| JP (3) | JP2012517592A (enExample) |
| CN (3) | CN102369293B (enExample) |
| AU (1) | AU2010210535B2 (enExample) |
| BR (1) | BRPI1007917A2 (enExample) |
| CA (1) | CA2751424A1 (enExample) |
| HK (1) | HK1200218A1 (enExample) |
| MX (1) | MX2011008323A (enExample) |
| NZ (1) | NZ630621A (enExample) |
| WO (1) | WO2010091231A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9057735B2 (en) | 2008-08-29 | 2015-06-16 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2766228A1 (en) * | 2009-07-02 | 2011-01-06 | Mosaiques Diagnostics And Therapeutics Ag | Process and markers for the diagnosis of acute renal failure |
| JP2013541005A (ja) * | 2010-09-24 | 2013-11-07 | アスチュート メディカル，インコーポレイテッド | ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物 |
| EP2882767B1 (en) * | 2012-08-11 | 2023-07-12 | Astute Medical, Inc. | Evaluating renal injury using hyaluronic acid |
| HK1219129A1 (zh) * | 2013-01-29 | 2017-03-24 | 阿斯图特医药公司 | 用於肾损伤和肾衰竭的诊断及预後的方法和组合物 |
| CN105917229B (zh) * | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| CN105466984B (zh) * | 2016-01-14 | 2018-12-28 | 郑以山 | 用于肾脏非显性损伤的预警装置及其使用方法 |
| WO2017130985A1 (ja) * | 2016-01-29 | 2017-08-03 | 株式会社国際電気通信基礎技術研究所 | 腎機能の評価装置、腎疾患の合併症の発症の予測装置、およびリン摂取量推定装置 |
| CN106845140A (zh) * | 2017-03-01 | 2017-06-13 | 重庆工商大学 | 一种基于尿比重和尿量监测的肾衰竭预警方法及系统 |
| MX2019014441A (es) * | 2017-05-30 | 2020-02-10 | Sphingotec Gmbh | Un metodo in vitro para diagnosticar o monitorear la funcion renal o diagnosticar disfuncion renal. |
| CN109897108B (zh) * | 2019-03-11 | 2021-04-02 | 上海恒赛生物科技有限公司 | 抗人内皮蛋白c受体的羊驼单域抗体及应用 |
| EP3881862A1 (de) * | 2020-03-18 | 2021-09-22 | Pharis Biotec GmbH | Polypeptid zur therapie von glomerulären nierenerkrankungen und analyse des verlaufes und prognose der abhängigen syndrome |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3569577B2 (ja) * | 1995-09-04 | 2004-09-22 | 株式会社いかがく | 腎・尿路系疾患の鑑別診断用キット |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
| JP2003030100A (ja) * | 2001-07-12 | 2003-01-31 | Fuji Xerox Co Ltd | インターネット情報提供システムおよびインターネット情報提供方法 |
| ES2268961B1 (es) * | 2005-03-17 | 2008-03-16 | Proyecto De Biomedicina Cima, S.L. | Nueva proteina epcr soluble de origen no proteolitico y su uso. |
| US7833732B2 (en) * | 2005-07-21 | 2010-11-16 | The John Hopkins University | Acute renal injury |
| TW200726845A (en) * | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
| US7662578B2 (en) * | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| US20080038269A1 (en) * | 2006-05-25 | 2008-02-14 | Mount Sinai Hospital | Methods for detecting and treating kidney disease |
| GB0617429D0 (en) * | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| EP2095107B1 (en) * | 2006-11-14 | 2014-07-02 | Alere San Diego, Inc. | Methods for risk assignment |
| JP5661457B2 (ja) * | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
-
2010
- 2010-02-05 EP EP10739150A patent/EP2393937A4/en not_active Withdrawn
- 2010-02-05 AU AU2010210535A patent/AU2010210535B2/en not_active Ceased
- 2010-02-05 JP JP2011549275A patent/JP2012517592A/ja active Pending
- 2010-02-05 CN CN201080013522.5A patent/CN102369293B/zh not_active Expired - Fee Related
- 2010-02-05 WO PCT/US2010/023292 patent/WO2010091231A1/en not_active Ceased
- 2010-02-05 NZ NZ630621A patent/NZ630621A/en not_active IP Right Cessation
- 2010-02-05 CN CN201611051979.0A patent/CN106546752A/zh active Pending
- 2010-02-05 BR BRPI1007917A patent/BRPI1007917A2/pt not_active IP Right Cessation
- 2010-02-05 MX MX2011008323A patent/MX2011008323A/es active IP Right Grant
- 2010-02-05 CA CA2751424A patent/CA2751424A1/en not_active Abandoned
- 2010-02-05 CN CN201410171245.0A patent/CN104111336B/zh not_active Expired - Fee Related
-
2015
- 2015-01-20 HK HK15100634.5A patent/HK1200218A1/xx unknown
- 2015-01-27 JP JP2015013153A patent/JP2015096870A/ja active Pending
-
2016
- 2016-01-04 US US14/987,569 patent/US20160123996A1/en not_active Abandoned
- 2016-07-04 JP JP2016132688A patent/JP2016194526A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517592A5 (enExample) | ||
| JP2012517594A5 (enExample) | ||
| JP2013519095A5 (enExample) | ||
| JP2012517593A5 (enExample) | ||
| JP2013539030A5 (enExample) | ||
| JP2014529073A5 (enExample) | ||
| JP2013501920A5 (enExample) | ||
| JP2016505143A5 (enExample) | ||
| JP2013503344A5 (enExample) | ||
| Husain-Syed et al. | Persistent decrease of renal functional reserve in patients after cardiac surgery-associated acute kidney injury despite clinical recovery | |
| JP2013510321A5 (enExample) | ||
| JP4879993B2 (ja) | Ｎｇａｌを使用する慢性腎疾患の診断および監視 | |
| Kusaka et al. | Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death | |
| HRP20160733T1 (hr) | Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije | |
| JP2013510322A5 (enExample) | ||
| JP2013539861A5 (enExample) | ||
| JP2021039112A5 (enExample) | ||
| TR201807542T4 (tr) | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. | |
| JP2015129764A5 (enExample) | ||
| JP2013513086A5 (enExample) | ||
| JP2013519866A5 (enExample) | ||
| JP2017533427A5 (enExample) | ||
| Roehm et al. | Novel biomarkers of kidney disease in advanced heart failure: beyond GFR and proteinuria | |
| JP2015508181A5 (enExample) | ||
| Wohlfahrtova et al. | New strategies for evaluating the quality of kidney grafts from elderly donors |